加德纳氏症治疗市场－全球产业规模、份额、趋势、机会及预测（按癌症类型、治疗药物类型、最终用户、地区和竞争格局划分，2021-2031年）

全球加德纳氏症治疗市场预计将从 2025 年的 203.1 亿美元成长到 2031 年的 275.5 亿美元，复合年增长率达到 5.21%。

针对这种遗传性疾病的治疗策略包括切除术等外科手术，以及非类固醇消炎剂(NSAIDs) 和 COX-2 抑制剂等药物治疗，以控制多发性息肉和结肠外表现。市场成长的主要驱动力是先进基因筛检技术的日益普及，这些技术能够实现早期诊断，以及临床上对预防性护理（防止良性息肉恶性转化）的日益关注。

然而，终身监测和复杂手术带来的巨大经济负担仍然是市场广泛接受该疗法的一大障碍。美国癌症协会的报告显示，预计到2024年，美国将有约152,810人被诊断出患有结直肠癌，这凸显了肠道病变和遗传风险管理方面的迫切需求。如此高的发病率表明，即使经济障碍仍然阻碍着市场的进一步扩张，有效的治疗方案仍然至关重要。

市场驱动因素

基因筛检和次世代定序技术的进步，使得精准检测大肠腺瘤性息肉病基因突变成为可能，并成为市场成长的主要驱动力。这些诊断工具使临床医生能够在肠外症状或癌症出现之前製定监测通讯协定，以便及时进行手术或药物干预。肠道疾病在全球日益增长的影响，进一步凸显了对这类早期检测系统的需求。区分遗传性和散发性病例需要强大的检测能力。根据世界卫生组织（世卫组织）2024年2月发布《全球癌症负担》的新闻稿，大肠直肠癌是全球第三大常见癌症，2022年估计新增病例达190万例。

同时，对罕见疾病和疑难杂症药物研发投入的增加正在扩大市场。在有利于罕见疾病药物研发的监管环境下，製药公司获得了更大的奖励，这些法规环境提供市场独占权和税收优惠，从而推动了研发重点从单纯的外科手术治疗转向药物预防。根据美国食品药物管理局（FDA）于2024年1月发布的《2023年新药核准报告》，2023年核准的55种新疗法中有28种被指定用于治疗罕见疾病，这标誌着製药业正持续转向满足遗传性疾病领域未被满足的医疗需求。此外，死亡率数据也印证了开发这些治疗方法的迫切性。根据美国癌症协会（ACS）的预测，到2024年，美国大肠癌死亡人数预计将达到53,010人，这将导致对更有效药物的需求不断增长，以提高患者的存活率。

市场挑战

加纳症候群治疗领域发展的一大障碍是终身后续观察和复杂手术带来的沉重经济负担。患有这种遗传性疾病的患者需要持续的医疗管理，包括频繁的内视镜检查和诸如切除术等大规模的干预措施，以降低癌症风险，这导致高昂的直接医疗费用限制了患者获得标准治疗的机会。由于无力承受必要的预防性治疗方案，患者对治疗通讯协定的遵从性较差，导致手术量减少，对药物治疗的需求也随之降低。

根据美国癌症协会癌症控制网络（ACS CAN）2024年的报告，约47%的患者和倖存者表示难以支付癌症相关费用，包括筛检和治疗费用。这种普遍存在的经济负担表明，很大一部分潜在患者可能由于经济压力而推迟或放弃重要的后续观察和手术。因此，由于经济限制阻碍了必要治疗方法的广泛普及，市场面临商机。

市场趋势

受临床对降低手术创伤和在预防性肠切除术中保护神经功能的需求驱动，微创机器人辅助切除术正成为该领域的一大趋势。机器人系统越来越受到青睐，尤其是在髂骨储袋肛管吻合术等重组手术中，因为在狭窄的骨盆腔内进行精准操作对于减少併发症至关重要。这项技术的融合正在迅速重新定义遗传性大肠直肠疾病的手术标准。根据Intuitive公司于2025年1月发布的“2024年第四季及全年初步财务业绩报告”，2024年全球达文西手术量将同比增长约17%，这反映出机器人技术在复杂腹部手术中的应用日益广泛。

同时，γ-分泌酶抑制剂的引入标誌着纤维瘤（一种危及生命的加德纳氏症结肠外表现）治疗领域的变革性进展。这一趋势代表着治疗方法的转变，从高风险、易復发的手术切除转向标靶药物抑制Notch讯号通路，进而诱导肿瘤消退。这些新型疗法的强劲商业性应用凸显了对有效非手术治疗方案的迫切需求。根据SpringWorks Therapeutics于2025年2月发布的“2024年第四季度及全年财务业绩报告”，该公司2024年全年OGSIVEO（nirogacestat）在美国的净产品销售额为1.72亿美元，表明已通过核准的全身性疗法在以往服务不足的患者群体中获得了显着的市场认可。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球加德纳氏症治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 癌症类型（扩大性心肌病、骨骼肌肉病变、嗜中性白血球低下症、其他）
  • 依治疗方法（非类固醇消炎剂（NSAIDs）、COX-2抑制剂）
  • 按最终使用者（医院/诊所、门诊护理中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美加德纳氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲加德纳氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区加德纳症候群治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲加德纳氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲加德纳氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球加德纳氏症治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Biochem Pharmaceuticals Industries Limited
• Zydus Lifesciences Limited
• Vernalis（R&D）Limited
• Sun Pharmaceutical Industries Ltd.
• Sanofi SA
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Medimetriks Pharmaceuticals, Inc
• Johnson & Johnson Services, Inc.
• Akorn Operating Company LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Gardner Syndrome Treatment Market is projected to expand from USD 20.31 Billion in 2025 to USD 27.55 Billion by 2031, achieving a compound annual growth rate (CAGR) of 5.21%. Treatment strategies for this hereditary condition encompass surgical procedures, such as colectomy, alongside pharmacological therapies like NSAIDs and COX-2 inhibitors intended to control polyposis and extracolonic symptoms. The market is largely propelled by the increasing application of sophisticated genetic screening technologies that enable early diagnosis, combined with a growing clinical focus on prophylactic care designed to stop benign polyps from advancing into malignancies.

Nevertheless, the significant economic costs associated with lifelong monitoring and intricate surgeries pose a major obstacle to broad market accessibility. As reported by the American Cancer Society, approximately 152,810 individuals in the United States are expected to be diagnosed with colorectal cancer in 2024, a figure that emphasizes the substantial need for managing bowel pathologies and genetic risks. This high prevalence highlights the critical necessity for effective therapeutic solutions, even as financial barriers continue to hinder wider market expansion.

Market Driver

The advancement of genetic screening and Next-Generation Sequencing technologies acts as a primary engine for market growth by allowing for the precise detection of Adenomatous Polyposis Coli gene mutations. These diagnostic tools enable clinicians to establish surveillance protocols before the appearance of extracolonic manifestations or cancer, thereby facilitating prompt surgical or pharmacological action. The necessity for such early detection systems is heightened by the rising global impact of bowel pathologies, which requires robust testing frameworks to distinguish hereditary cases from sporadic ones; according to the World Health Organization's 'Global Cancer Burden' press release from February 2024, colorectal cancer was the third most common cancer globally, with an estimated 1.9 million new cases in 2022.

Simultaneously, the market is growing due to increased investment in research and development for orphan drugs and rare disease therapeutics. Pharmaceutical companies are finding greater incentive in supportive regulatory environments that offer market exclusivity and tax benefits for creating treatments for low-prevalence conditions, shifting the focus from purely surgical management to pharmacological prevention. According to the U.S. Food and Drug Administration's 'New Drug Therapy Approvals 2023' report from January 2024, 28 of the 55 novel drugs approved in 2023 were designated for rare diseases, indicating a sustained industry pivot toward addressing unmet needs in hereditary conditions. Furthermore, the urgency of developing these treatments is underscored by mortality data; the American Cancer Society projects that colorectal cancer will cause 53,010 deaths in the United States in 2024, driving the demand for more effective drugs to improve patient survival.

Market Challenge

The considerable economic strain linked to lifelong surveillance and complex surgical procedures serves as a major barrier to the growth of the Gardner Syndrome treatment sector. Patients with this hereditary condition need continuous medical management, including frequent endoscopic exams and major interventions like colectomy to lower cancer risks, which result in high direct medical costs that limit patient access to standard care. When individuals are unable to afford the necessary prophylactic regimen, adherence to treatment protocols drops, effectively reducing the volume of surgeries performed and the demand for pharmacological management options.

According to the American Cancer Society Cancer Action Network in 2024, roughly 47 percent of patients and survivors reported difficulty covering costs associated with cancer care, including screening and treatment expenses. This widespread financial toxicity suggests that a large segment of the potential patient population may delay or forgo critical monitoring and surgery due to economic pressures. Consequently, the market faces diminished revenue opportunities as financial constraints restrict the widespread adoption of essential therapeutic interventions.

Market Trends

The sector is witnessing a significant transition toward minimally invasive and robotic proctocolectomy, driven by the clinical need to reduce surgical trauma and preserve nerve function during prophylactic bowel removal. Robotic systems are increasingly preferred over open techniques due to their enhanced precision within the narrow pelvic cavity, which is essential for minimizing complications during restorative procedures like ileal pouch-anal anastomosis. This technological integration is rapidly redefining surgical standards for hereditary colorectal conditions; according to the 'Intuitive Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results' press release from January 2025, worldwide da Vinci procedures increased by approximately 17 percent in 2024 compared to the previous year, reflecting the expanding scale of robotic adoption in complex abdominal interventions.

At the same time, the introduction of gamma-secretase inhibitors marks a transformative step in managing desmoid tumors, a life-threatening extracolonic manifestation of Gardner Syndrome. This trend indicates a therapeutic shift from high-risk surgical resections, which often lead to recurrence, toward targeted pharmacological suppression of the Notch signaling pathway to induce tumor regression. The strong commercial uptake of these novel therapeutics highlights the urgent demand for effective non-surgical options; according to SpringWorks Therapeutics' 'Fourth Quarter and Full Year 2024 Financial Results' report from February 2025, the company recorded full-year 2024 U.S. net product revenue of $172.0 million for OGSIVEO (nirogacestat), validating the substantial market adoption of approved systemic therapies for this previously underserved patient segment.

Key Market Players

• Biochem Pharmaceuticals Industries Limited
• Zydus Lifesciences Limited
• Vernalis (R&D) Limited
• Sun Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Medimetriks Pharmaceuticals, Inc
• Johnson & Johnson Services, Inc.
• Akorn Operating Company LLC

Report Scope

In this report, the Global Gardner Syndrome Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gardner Syndrome Treatment Market, By Cancer Type

• Dilated Cardiomyopathy
• Skeletal Myopathy
• Neutropenia
• Others

Gardner Syndrome Treatment Market, By Therapeutics Type

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• COX-2 Inhibitor

Gardner Syndrome Treatment Market, By End user

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Gardner Syndrome Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gardner Syndrome Treatment Market.

Available Customizations:

Global Gardner Syndrome Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gardner Syndrome Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Dilated Cardiomyopathy, Skeletal Myopathy, Neutropenia, Others)
  • 5.2.2. By Therapeutics Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), COX-2 Inhibitor)
  • 5.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Gardner Syndrome Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Therapeutics Type
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gardner Syndrome Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Therapeutics Type
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Gardner Syndrome Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Therapeutics Type
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Gardner Syndrome Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Therapeutics Type
      • 6.3.3.2.3. By End user

7. Europe Gardner Syndrome Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Therapeutics Type
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gardner Syndrome Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Therapeutics Type
      • 7.3.1.2.3. By End user
  • 7.3.2. France Gardner Syndrome Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Therapeutics Type
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Gardner Syndrome Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Therapeutics Type
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Gardner Syndrome Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Therapeutics Type
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Gardner Syndrome Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Therapeutics Type
      • 7.3.5.2.3. By End user

8. Asia Pacific Gardner Syndrome Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Therapeutics Type
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gardner Syndrome Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Therapeutics Type
      • 8.3.1.2.3. By End user
  • 8.3.2. India Gardner Syndrome Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Therapeutics Type
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Gardner Syndrome Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Therapeutics Type
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Gardner Syndrome Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By Therapeutics Type
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Gardner Syndrome Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By Therapeutics Type
      • 8.3.5.2.3. By End user

9. Middle East & Africa Gardner Syndrome Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Therapeutics Type
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Gardner Syndrome Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Therapeutics Type
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Gardner Syndrome Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Therapeutics Type
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Gardner Syndrome Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Therapeutics Type
      • 9.3.3.2.3. By End user

10. South America Gardner Syndrome Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Therapeutics Type
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gardner Syndrome Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Therapeutics Type
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Gardner Syndrome Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Therapeutics Type
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Gardner Syndrome Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Therapeutics Type
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gardner Syndrome Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Biochem Pharmaceuticals Industries Limited
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Zydus Lifesciences Limited
• 15.3. Vernalis (R&D) Limited
• 15.4. Sun Pharmaceutical Industries Ltd.
• 15.5. Sanofi S.A.
• 15.6. Novartis AG
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Medimetriks Pharmaceuticals, Inc
• 15.9. Johnson & Johnson Services, Inc.
• 15.10. Akorn Operating Company LLC

16. Strategic Recommendations

17. About Us & Disclaimer